<DOC>
	<DOCNO>NCT01014338</DOCNO>
	<brief_summary>A double blind randomise placebo control parallel trial effect fosinopril , angiotensin convert enzyme inhibitor , quadriceps muscle 80 COPD patient quadriceps weakness . Patients baseline assessment include measure quadriceps strength endurance quadriceps biopsy . Patients weakness randomise ACE inhibitor placebo re-assessed three month treatment . The investigator aim show ACE-inhibition alter IGF-1/AKT/FoXO/atrogene pathway involve muscle waste COPD .</brief_summary>
	<brief_title>Angiotensin-converting Enzyme ( ACE ) -Inhibition Mechanisms Skeletal Muscle Weakness Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Muscle Weakness</mesh_term>
	<mesh_term>Paresis</mesh_term>
	<mesh_term>Fosinopril</mesh_term>
	<criteria>Adult patient COPD diagnose accord GOLD criterion . Clinically unstable patient ( within one month exacerbation ) , permanent pacemaker ( contraindication magnetic stimulation ) , significant comorbidity , patient accept indication ACE inhibition ( left ventricular dysfunction , diabetes ) contraindication renovascular disease ; creatinine clearance ( estimate ) &lt; 50 ) ; hypotension ; use anticoagulant ( contraindication biopsy ) ACEI ATII receptor antagonist . Allergy ACEinhibitors . Pregnancy . Patients enrol within three month participation pulmonary rehabilitation program .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>